Table 2. Serum cytokine profile before and after rituximab treatment.
| Cytokine | day –28 [pg/ml]1 | day 82 [pg/ml]1 | change |
|---|---|---|---|
| IL-1b | <1.91 | 20.82 ± 7.78 | +++ |
| IL-1RA | 314.04 ± 11.67 | 772.17 ± 6.36 | ++ |
| IL-2 | <1.03 | <1.03 | o |
| IL-4 | 5.17 ± 9.90 | 31.09 ± 18.74 | + |
| IL-5 | <1.82 | <1.82 | o |
| IL-6 | 37.58 ± 28.64 | 18.84 ± 3.54 | o |
| IL-7 | 16.47 ± 7.07 | 15.43 ± 2.83 | o |
| IL-8 | 28.43 ± 26.16 | 18.29 ± 3.18 | o |
| IL-9 | 23.94 ± 3.18 | 71.08 ± 2.41 | ++ |
| IL-10 | <1.53 | 30.19 ± 22.63 | ++ |
| IL-12(p70) | 31.97 ± 9.90 | 99.51 ± 9.19 | ++ |
| IL-13 | <2.22 | 21.77 ± 1.77 | +++ |
| IL-15 | <1.69 | <1.69 | o |
| IL-17 | 15.85 ± 4.95 | 13.65 ± 2.83 | o |
| Eotaxin | <6.51 | 85.27 ± 5.30 | +++ |
| bFGF | 24.08 ± 7.42 | 25.41 ± 0.71 | o |
| G-CSF | 57.64 ± 3.18 | 120.95 ± 1.06 | ++ |
| GM-CSF | 43.31 ± 54.45 | 130.24 ± 12.73 | ++ |
| IFN-g | 175.83 ± 11.31 | 1000.62 ± 19.09 | +++ |
| CXCL10 | 635.84 ± 172.89 | 1787.78 ± 8.49 | ++ |
| CCL2 | 32.78 ± 62.93 | 85.83 ± 10.61 | o |
| CCL3 | 11.96 ± 20.15 | 16.71 ± 0.71 | o |
| CCL4 | 129.09 ± 250.32 | 217.72 ± 14.14 | o |
| PDGF-bb | 8051.16 ± 873.28 | 6977.90 ± 57.28 | - |
| TNF-a | <19.18 | 153.91 ± 8.49 | +++ |
| VEGF | 144.04 ± 47.73 | 87.91 ± 1.77 | - |
1
mean +/− SD; < below detection level;
+ increase < 2fold; ++ increase ≥ 2fold; +++ increase ≥ 5fold;
- decrease < 2fold; - - decrease ≥ 2fold; - - - decrease ≥ 5fold;
o no significant change